The effectiveness of STI571 in the earlier stages of the disease resulted in an expansion of these phase I studies to include CML patients in myeloid and lymphoid blast crisis and patients with relapsed or non-responsive BCR–ABL positive ALL. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.